Research programme: oligonucleotide therapeutics for diabetes - OliPass
Latest Information Update: 12 Jul 2016
At a glance
- Originator OliPass
- Class Oligonucleotides
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetes mellitus
Most Recent Events
- 12 Jul 2016 Early research in Diabetes mellitus in South Korea (unspecified route)